SCHEMBL5130095

SCHEMBL5130095

FC(F)(F)c1ccc(-n2cc(Br)cn2)cc1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 1/20 0.50
PKM P14618 1/20 0.50
KMT2A Q03164 1/20 0.50
NOTUM Q6P988 1/20 0.44
EPHX2 P34913 1/20 0.43
KDM4E B2RXH2 2/20 0.42
ALDH1A1 P00352 2/20 0.42
HPGD P15428 2/20 0.42
MAPT P10636 1/20 0.42
XBP1 P17861 1/20 0.42
NTRK1 P04629 1/20 0.41
FLT3 P36888 1/20 0.41
GRM4 Q14833 1/20 0.39
MAOB P27338 1/20 0.39
SMN1; SMN2 Q16637 1/20 0.39
NPSR1 Q6W5P4 1/20 0.39
AHR P35869 1/20 0.38
SRC P12931 1/20 0.38
BRAF P15056 1/20 0.38
KDR P35968 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19521416 0.80 EPHX2 (0.68) MEN1KMT2ANOTUMEPHX2KDM4E
SCHEMBL15008954 0.79 MEN1 (0.47) MEN1PKMKMT2ANOTUMALDH1A1
SCHEMBL24857473 0.79 NOTUM (0.44) MEN1KMT2ANOTUMEPHX2KDM4E
SCHEMBL12818406 0.79 NOTUM (0.44) NOTUMEPHX2NTRK1FLT3GRM4
SCHEMBL19120855 0.79 NOTUM (0.44) MEN1KMT2ANOTUMEPHX2NTRK1
SCHEMBL27496862 0.79 NOTUM (0.44) NOTUMEPHX2KDM4EALDH1A1HPGD
SCHEMBL12151213 0.78 NOTUM (0.44) NOTUMEPHX2NTRK1FLT3GRM4
SCHEMBL1229886 0.78 RXRA (0.43) MEN1PKMKMT2AKDM4EALDH1A1
SCHEMBL22925831 0.78 HDAC4 (0.49) MEN1KMT2AKDM4EALDH1A1HPGD
SCHEMBL29620876 0.78 HDAC4 (0.49) MEN1KMT2AKDM4EALDH1A1HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-114450281-B Inhibitor compounds 辛塞拉治疗私人有限公司 2024-08-16 CN disclosed
CN-116964045-A Oxamide compounds and compositions for the treatment of diseases associated with STING activity 艾福姆德尤股份有限公司 2023-10-27 CN disclosed
WO-2022150549-A1 OXALAMIDE COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY IFM DUE, INC. (US) 2022-07-14 WO disclosed
CN-114450281-A Inhibitor compounds 辛塞拉治疗私人有限公司 2022-05-06 CN disclosed
WO-2021012018-A1 INHIBITOR COMPOUNDS Cincera Therapeutics Pty Ltd (AU) 2021-01-28 WO disclosed
US-20080249137-A1 PPAR active compounds PLEXXIKON INC 2008-10-09 US disclosed
US-20080249137-A1 PPAR active compounds PLEXXIKON INC 2008-10-09 US disclosed
US-20080249137-A1 PPAR active compounds PLEXXIKON INC 2008-10-09 US disclosed
EP-1940767-A2 PPARACTIVE COMPOUNDS PLEXXIKON, INC. (US) 2008-07-09 EP disclosed
WO-2007030567-A2 PPARACTIVE COMPOUNDS PLEXXIKON, INC. (US) 2007-03-15 WO disclosed
WO-2007030567-A2 PPARACTIVE COMPOUNDS PLEXXIKON, INC. (US) 2007-03-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080249137-A1 PPAR active compounds PPARG, PPARA, PPARD MEN1 4864/4885PKM 813/4885KMT2A 4098/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.